Home

Stephen N. Oesterle

CIK 1174532 · SrVP Medicine & Technology · last filed 2025-05-08

Stephen N. Oesterle is a SrVP Medicine & Technology who has filed 36 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for BAX, was dated May 18, 2026. Across all open-market trades the lifetime net is −$694.3K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.5M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.45M

Companies

5

Total Filings

36

Lifetime Open-Market Net

-$694.3K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BAX Director 35,847 $24.70 $885.6K $0 10 2025-05-08
Paragon 28, Inc. (FNA) Delisted Director 0 $13.09 $0 $0 5 2025-04-21
Sigilon Therapeutics, Inc. (SGTX) Delisted Director — $22.47 — $0 5 2023-08-11
HeartWare International, Inc. (HTWR) Delisted Director 0 — — $32.2K 4 2016-08-24
MDT SrVP Medicine & Technology 52,209 $87.44 $4.57M -$726.5K 9 2009-08-05

Recent Filings

36 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-18 BAX Notice (144) −36,347 -$645.2K EDGAR
2025-05-08 BAX Grant (A) +7,183 $0 EDGAR
2025-04-21 Paragon 28, Inc. (FNA) Delisted Disp (D) −40,216 $0 EDGAR
2024-05-21 Paragon 28, Inc. (FNA) Delisted Grant (A) +15,906 $0 EDGAR
2024-05-09 BAX Grant (A) +5,952 $0 EDGAR
2023-08-11 Sigilon Therapeutics, Inc. (SGTX) Delisted Disp (D) — $0 EDGAR
2023-05-22 Sigilon Therapeutics, Inc. (SGTX) Delisted Grant (A) — $0 EDGAR
2023-05-19 Paragon 28, Inc. (FNA) Delisted Grant (A) +8,361 $0 EDGAR
2023-05-04 BAX Grant (A) +4,573 $0 EDGAR
2023-02-22 Paragon 28, Inc. (FNA) Delisted Grant (A) +8,918 $0 EDGAR
Showing 1–10 of 36
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.